WO1987000754A1 - Laxatif a faible teneur en sodium et compositions de lavage - Google Patents

Laxatif a faible teneur en sodium et compositions de lavage Download PDF

Info

Publication number
WO1987000754A1
WO1987000754A1 PCT/US1986/001578 US8601578W WO8700754A1 WO 1987000754 A1 WO1987000754 A1 WO 1987000754A1 US 8601578 W US8601578 W US 8601578W WO 8700754 A1 WO8700754 A1 WO 8700754A1
Authority
WO
WIPO (PCT)
Prior art keywords
ions
solution
milliequivalents
sodium
polyethylene glycol
Prior art date
Application number
PCT/US1986/001578
Other languages
English (en)
Inventor
John S. Fordtran
Original Assignee
Braintree Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Braintree Laboratories, Inc. filed Critical Braintree Laboratories, Inc.
Publication of WO1987000754A1 publication Critical patent/WO1987000754A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • This invention is in the field of medicine.and in particular relates to the treatment of constipa- tion and to colon cleansing necessary, for example, prior to diagnostic procedures or surgery.
  • Constipation is a common and often serious problem for which numerous treatments have been developed. None of these, however, has proved to be entirely successful and many have serious limita ⁇ tions. For example, dietary manipulations (e.g., increasing the fiber content of the diet, removing foods thought to have a constipating effect) , laxatives and enemas are three commonly used ap ⁇ proaches to solving the problem. However, these approaches have important limitations, such as their ability to produce the desired effect; user accep ⁇ tance and compliance; and gas production (e.g., as a result of metabolism of fiber or carbohydrates, such as lactulose, by intestinal bacteria) .
  • Colon cleansing is very important prior to a number of diagnostic or surgical procedures. For example, thorough cleansing of the colon is said to be "essential to a successful diagnostic barium enema" and "one of the most important steps in the diagnosis of early colon cancer.” Davis, G.R. and H.R. Smith, Gastrointestinal Radiology, : 173-176 (1983) . Colon cleansing is also necessary before colonscopy or colon surgery. A variety of methods can be used for colon cleansing; each, however, has important shortcomings and none is wholly successful.
  • laxatives and enemas are traditionally used for colon cleansing.
  • Thomas and co-workers have shown that clear liquids for 48 hours, in combination with laxatives and enemas, are relatively successful in producing a feces-free colon.
  • Thomas, G. et al. Gastroenterology, 82; 435-437 (1982) .
  • These approaches are time consum- ing, inconvenient and unpleasant for the patient. Potentially harmful salt and water losses may occur when cathartics and enemas are used.
  • Davis, G. et al. Gastroenterology, 78; 9131-995 (1980).
  • the solution described contains sodium chloride, potassium chloride, sodium bi ⁇ carbonate, polyethylene glycol or mannitol and water.
  • the resulting solution has been shown to be effective in cleansing the gastrointestinal tract but it has disadvantages which interfere with its use. For example, patient acceptance can be a problem because of the solution's flavor, which is highly salty.
  • There is a need for a method of treating constipation which is not only effective, but also acceptable.
  • there are many methods which can be used for colon cleansing prior to diagnostic or surgical procedures none is without limitations.
  • a method of colon cleansing which is safe, more effective and better accepted by users than presently available methods.
  • the present invention relates to a formulation for the treatment of constipation and for colon cleansing, as well as a method for its use in treating constipation and producing cleansing of the colon.
  • the formulation is comprised of polyethylene glycol (PEG) , which, in the treatment of constipa ⁇ tion, can be administered alone in an aqueous solution or can be administered in combination with electrolytes in an aqueous solution.
  • PEG polyethylene glycol
  • In intestinal lavage PEG is administered in combination with electrolytes in an aqueous solution.
  • the polyethylene glycol solution is administered in sufficient quantities to produce a soft stool.
  • the polyethylene glycol-electrolyte solution is administered orally or nasogastrically in sufficient quantities to produce rapid and thorough evacuation of the gastrointestinal tract. If electrolytes are present in the solution, they occur in amounts that will prevent a net loss of electrolytes from the body as a result of consumption of the solution.
  • the sodium concentration of the formulation of the present invention is considerably lower than in the sodium-sulfate-based lavage solutions now in use. Therefore, the lavage solution does not have a salty taste, as do the sodium-sulfate-based solutions.
  • PEG is poorly absorbed or not absorbed at all in the gastrointestinal tract; in addition, it is not fermented by coIonic bacteria; therefore, PEG is not metabolized to products which can be absorbed or to gaseous products (such as hydrogen gas) which can cause patient discomfort (e.g., flatulence).
  • gaseous products such as hydrogen gas
  • mannitol which is also poorly absorbed, is fermentable by colonic bacteria and some of the fermentation products are absorbed in the colon; some of the fermentation products are gases.
  • the figure represents graphically the secretion and absorption of water and electrolytes after lavage with a balanced electrolyte solution (BES) , Golytely (GL) or the low sodium-PEG lavage solution of the present invention.
  • BES balanced electrolyte solution
  • GL Golytely
  • PEG in sufficient quantity in an aqueous solution to produce a soft stool can be used for treatment of constipation.
  • PEG in an aqueous solution can be administered orally or nasogastrically to effectuate rapid evacuation of the gastrointestinal tract.
  • PEG can be administered alone or in combination with electrolytes.
  • electrolytes are present in sufficient quantities to prevent a net electrolyte loss , from the body.
  • Electrolytes included in a solution of the present invention include sodium ions, potassium ions chloride ions, and bicarbonate ions, alone or in any desired combination.
  • the PEG solution of the PEG- electrolyte solution can also contain flavoring material, such as Crystal Light , aspartame or other suitable flavoring agent.
  • the sodium concentration of the formulation of this invention is less than 100 milliequivalents per liter, and will generally be less than 75 milliequiva- lents per liter. In one preferred embodiment, the sodium concentration is about 65 milliequivalents per liter. This is much lower than the sodium concentration of the two sodium-sulfate based lavage solutions (Golytely and Colyte) currently available. (The sodium concentration of these two solutions is 125 milliequivalents per liter.) Because of its low sodium content, the solution of the present inven ⁇ tion does not have the highly salty taste complained of by users of presently available solutions.
  • PEG 3350 is present in water at a concentration of about 105 grams (gm) per liter of solution.
  • Each of the ions is present in a concentration of from about 2 to about 100 milliequivalents.
  • sodium ions are present in a concentra ⁇ tion of about 65 milliequivalents per liter, chloride in a concentration of about 53 milli ⁇ equivalents per liter, bicarbonate ions in a concen- tration of about 17 meq per liter and potassium ions in a concentration of about 5 meq per liter. .
  • PEG 3350 is present in water at a concentration of about 120 gm per liter of solution. In another embodiment, about 120 gm of PEG 3350 is present per liter of solution along with sodium ions, potassium ions, chloride ions and bicarbonate ions. Each of the ions is present in a concentration of from about 5.0 milli ⁇ equivalents per liter to about 50 milliequivalents per liter; in a preferred embodiment, they are present in a liter of solution in the following concentrations: sodium ions, 46.6 milliequivalents; potassium ions, 9.0 milliequivalents; chloride ions, 35.0 milliequivalents; and bicarbonate ions, 20.9 milliequivalents.
  • the PEG solution of this invention is made by combining PEG 3350 with sufficient water to make a liter of solution. For example, in one embodiment, about 105gm of PEG 3350 is combined with sufficient water to make a liter of solution. In another embodiment, about 120 gm. of PEG 3350 is combined with sufficient water to make a liter of solution. If the PEG solution is to contain electrolytes as well, sources of the ions listed above (in dry form) are combined with PEG and mixed in a standard blender. The PEG-electrolyte solution is made by combining the PEG-electrolyte mixture with enough water to make a liter of solution.
  • the electrolytes are each present in a concentration of from about 2 milliequivalents to about 100 milliequivalents per liter.
  • the total volume of solution necessary to produce colon cleansing varies from individual to individual; it generally will be from 3 to 4 liters, although some individuals will require smaller or larger quantities.
  • individuals are lavaged at the rate of 20 milliliters per minute with the PEG-electrolyte solution having about 120 gm. of PEG 3350, 1.68 grams sodium bicarbonate, 0.74 gm potassium chloride and 1.46 gm sodium chloride in sufficient water to make a liter of solution.
  • PEG-electro- lyte solution have the following components, each expressed as grams/liter of solution: PEG 3350, 105; sodium chloride, 2.80; sodium bicarbonate, 1.43 and potassium chloride, 0.37.
  • PEG 3350, 105; sodium chloride, 2.80; sodium bicarbonate, 1.43 and potassium chloride, 0.37 This invention is further illustrated by the examples given below which are not to be seen as limiting in any way.
  • Polyethylene glycol (PEG) was dissolved in water in the amounts shown in Table 1.
  • the osmolality of each solution was measured by freezing point depression. As shown in Table 1, as the concentration of PEG is increased, the osmolality increases disproportionately. For example, a solution containing 60gm PEG per liter is osmoti- cally equivalent to 40mOsm/ g. When the concentra ⁇ tion of PEG is doubled, to 120gm per liter of solution, the osmolality increases almost fourfold (to 156MOsm/Kg.) .
  • a normal subject was lavaged at the rate of 30 milliliters per minute (1.8 liters per hour) with a solution having the following composition: PEG concentration 120 g/L of solution*
  • the solution had been made by combining 120 gm. PEG; 1.68 gm. sodium bicarbonate (NaHCO ⁇ ) ; 0.74 gm. potassium chloride (KCl) ; and 1.46 gm. sodium chloride (NaCl) and adding sufficient water to make one liter of solution.
  • Results of colon cleansing with this solution were compared with results produced using a balanced electrolyte solution (BES) and Golytely (GL) . They are best described with reference to the figure.
  • Golytely is the tradename for the lavage solution, described by Davis and co-workers, which is based primarily on sodium sulfate (see above) .
  • the results with the low sodium-PEG solution of the present invention are indicated by an X, plotted in between results for the other two solutions.
  • PEG-3350 was present in the solution in a concen ⁇ tration of 31.30 mmol/liter.
  • the solution was warmed to room temperature and infused into the stomach at a pump speed of 20 ml/minute or 30 ml/minute.
  • the polyethylene present in the solution as an integral part of the formula ⁇ tion was also used as a nonabsorbable marker to assess water absorption or secretion (see below) .
  • BSP sulfabromphthalein
  • This invention has industrial application in the treatment of constipation, which is a common and often serious medical problem, and in cleansing of the colon, which is necessary, for example, prior to diagnostic and surgical procedures.

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La solution ci-décrite est destinée au traitement de la constipation et au nettoyage du côlon. La solution utilisée pour le traitement de la constipation peut consister en un glycol de polyéthylène ou un glycol de polyéthylène et des ions sodium, des ions potassium, des ions chlorure et des ions bicarbonate. La solution utilisée pour nettoyer le côlon consiste en du glycol de polyéthylène, des ions sodium, des ions potassium, des ions chlorure et des ions bicarbonate; les ions sont présents dans la solution en quantités suffisantes pour empêcher une perte ou un gain net d'électrolytes du corps du patient. Un procédé de traitement de la constipation et un procédé de nettoyage du côlon sont également décrits.
PCT/US1986/001578 1985-08-01 1986-07-31 Laxatif a faible teneur en sodium et compositions de lavage WO1987000754A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76157785A 1985-08-01 1985-08-01
US761,577 1991-09-18

Publications (1)

Publication Number Publication Date
WO1987000754A1 true WO1987000754A1 (fr) 1987-02-12

Family

ID=25062635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/001578 WO1987000754A1 (fr) 1985-08-01 1986-07-31 Laxatif a faible teneur en sodium et compositions de lavage

Country Status (4)

Country Link
EP (1) EP0231356A1 (fr)
JP (1) JP2509594B2 (fr)
AU (1) AU6196786A (fr)
WO (1) WO1987000754A1 (fr)

Cited By (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3807712A1 (de) * 1987-07-25 1989-02-02 Nordend Apotheke Angela Hein Arzneimittel-trockenpraeparat zur bereitung einer laxativ wirkenden trinkloesung sowie ein verfahren zur herstellung dieses praeparates
EP0298655A3 (en) * 1987-07-10 1989-03-08 E-Z-Em, Inc. Aqueous cathartic solution
EP0396165A1 (fr) * 1989-04-17 1990-11-07 GIULIANI S.p.A. Composition pharmaceutique orale utilisée pour les lavages gastro-intestinaux, en particulier pour l'utilisation diagnostique, ou comme laxatif cathartique
EP0397689A1 (fr) * 1987-12-24 1990-11-22 Borody Thomas J Solutions de lavement orthostatique.
DE3924570A1 (de) * 1989-07-25 1991-01-31 Henning Berlin Gmbh Pharmazeutische zubereitung zur rektalen verabreichung
US5077048A (en) * 1988-07-13 1991-12-31 Morishita Pharmaceutical Co., Ltd. Bowel lavage composition
US5525355A (en) * 1993-09-14 1996-06-11 Euro-Celtique, S.A. Laxative compositions
WO1997003685A1 (fr) * 1995-07-14 1997-02-06 Halow George M Composition laxative/antidiarrheique comprenant du polyethylene-glycol et un agent fibreux augmentant le volume du bol fecal
EP0900562A1 (fr) * 1997-09-05 1999-03-10 Nissho Corporation Solution pour le nettoyage de l'intestin
EP1048297A2 (fr) * 1999-04-20 2000-11-02 Braintree Laboratories, Inc. Utilisation du polyethylene glycol pour reduire les gaz intestinaux, les crampes et l'irritation anorectale
US6444198B1 (en) 1999-02-22 2002-09-03 Smithkline Beecham Corporation Effervescent laxatives
WO2005049049A1 (fr) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Concentre de solution peg therapeutique
WO2005102364A1 (fr) * 2004-04-23 2005-11-03 Norgine Europe Bv Compositions pharmaceutiques comprimees comprenant peg et des electrolytes
US7169381B2 (en) 2002-10-25 2007-01-30 Norgine Europe Bv Colon cleansing compositions and methods
ES2278537A1 (es) * 2006-01-30 2007-08-01 Laboratorios Casen-Fleet, S.L. Procedimiento de fabricacion de una solucion a base de polietilenglicol con electrolitos, producto obtenido y uso.
US7495063B2 (en) 2006-02-03 2009-02-24 Dow Global Technologies Inc. Reduced oligomer concentration in high purity polyalkylene glycols
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
GB2472324A (en) * 2009-07-30 2011-02-02 Norgine Bv Polyethylene glycol and electrolyte lavage comprising preservatives for the treatment of constipation or faecal impaction
EP2322190A1 (fr) 2009-11-02 2011-05-18 Promefarm S.r.l. Agent de nettoyage intestinal et son utilisation
CN102573499A (zh) * 2009-04-21 2012-07-11 戴尔·R·巴赫威茨 结肠灌洗系统
WO2012102799A2 (fr) 2011-01-28 2012-08-02 Shaver William A Procédé, composition et module pour le nettoyage de l'intestin
WO2012120027A1 (fr) * 2011-03-08 2012-09-13 Norgine Bv Compositions pour lavement
US8597639B2 (en) 2006-08-28 2013-12-03 Miyarisan Pharmaceutical Co., Ltd. Adjunctive agent for lavaging the alimentary canal comprising butyric acid bacterium and/or lactic acid bacterium
US8999313B2 (en) 2012-09-11 2015-04-07 Norgine Bv Compositions
WO2016120684A1 (fr) * 2015-01-27 2016-08-04 Apharm S.R.L. Combinaison d'acide hyaluronique et de macrogol, et compositions pharmaceutiques la contenant
US9592252B2 (en) 2011-03-11 2017-03-14 Norgine Bv Colonoscopy—preparation

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA034234B1 (ru) 2013-03-15 2020-01-20 Брейнтри Лабораторис, Инк. Пероральные фармацевтические таблетированные композиции двойного применения, содержащие сульфат натрия или его комбинацию с другими сульфатными солями, и способы их получения и применения

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3495010A (en) * 1968-10-14 1970-02-10 Unimed Inc Method of effecting fecal softening

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3495010A (en) * 1968-10-14 1970-02-10 Unimed Inc Method of effecting fecal softening

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Unlisted Drugs, Volume 25, No. 3, March 1973 (Chatham, New Jersy, US), see page 39-e, "Alevac" *
Unlisted Drugs, Volume 36, No. 8, August 1984, (Chatham, New Jersey, US), see page 153-1, "Golytely" (cited in the application) *
Unlisted Drugs, Volume 37, No. 3, March 1985, (Chatham, New Jersey, US), see page 48-i "Colyte" (cited in the application) *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0298655A3 (en) * 1987-07-10 1989-03-08 E-Z-Em, Inc. Aqueous cathartic solution
DE3807712A1 (de) * 1987-07-25 1989-02-02 Nordend Apotheke Angela Hein Arzneimittel-trockenpraeparat zur bereitung einer laxativ wirkenden trinkloesung sowie ein verfahren zur herstellung dieses praeparates
EP0397689A4 (en) * 1987-12-24 1991-03-13 Thomas Julius Borody Orthostatic lavage solutions
EP0397689A1 (fr) * 1987-12-24 1990-11-22 Borody Thomas J Solutions de lavement orthostatique.
US5274001A (en) * 1987-12-24 1993-12-28 Borody Thomas J Orthostatic lavage solutions
US5077048A (en) * 1988-07-13 1991-12-31 Morishita Pharmaceutical Co., Ltd. Bowel lavage composition
EP0396165A1 (fr) * 1989-04-17 1990-11-07 GIULIANI S.p.A. Composition pharmaceutique orale utilisée pour les lavages gastro-intestinaux, en particulier pour l'utilisation diagnostique, ou comme laxatif cathartique
DE3924570A1 (de) * 1989-07-25 1991-01-31 Henning Berlin Gmbh Pharmazeutische zubereitung zur rektalen verabreichung
US5525355A (en) * 1993-09-14 1996-06-11 Euro-Celtique, S.A. Laxative compositions
WO1997003685A1 (fr) * 1995-07-14 1997-02-06 Halow George M Composition laxative/antidiarrheique comprenant du polyethylene-glycol et un agent fibreux augmentant le volume du bol fecal
EP0900562A1 (fr) * 1997-09-05 1999-03-10 Nissho Corporation Solution pour le nettoyage de l'intestin
US6121250A (en) * 1997-09-05 2000-09-19 Nissho Corporation Lavage solution for intestinal tract
US6444198B1 (en) 1999-02-22 2002-09-03 Smithkline Beecham Corporation Effervescent laxatives
EP1048297A2 (fr) * 1999-04-20 2000-11-02 Braintree Laboratories, Inc. Utilisation du polyethylene glycol pour reduire les gaz intestinaux, les crampes et l'irritation anorectale
EP1048297A3 (fr) * 1999-04-20 2002-05-08 Braintree Laboratories, Inc. Utilisation du polyethylene glycol pour reduire les gaz intestinaux, les crampes et l'irritation anorectale
RU2519562C2 (ru) * 2002-10-25 2014-06-10 Норджин Б.В. Сухая композиция для смешивания с водой, унифицированная доза, способ получения очистительного раствора для толстой кишки, водный раствор для очистки для толстой кишки и набор для очистки для толстой кишки (варианты)
US20100189815A1 (en) * 2002-10-25 2010-07-29 Norgine Bv Colon cleansing compositions and methods
US7169381B2 (en) 2002-10-25 2007-01-30 Norgine Europe Bv Colon cleansing compositions and methods
RU2519562C9 (ru) * 2002-10-25 2014-08-20 Норджин Б.В. Сухая композиция для смешивания с водой, унифицированная доза, способ получения очистительного раствора для толстой кишки, водный раствор для очистки толстой кишки и набор для очистки толстой кишки (варианты)
EP2014304A1 (fr) 2002-10-25 2009-01-14 Norgine Europe BV Compositions pour le nettoyage du colon
EP2314319A1 (fr) 2002-10-25 2011-04-27 Norgine Europe BV Compositions pour le nettoyage du colon
US7658914B2 (en) 2002-10-25 2010-02-09 Norgine Bv Colon cleansing compositions
WO2005049049A1 (fr) * 2003-11-17 2005-06-02 Braintree Laboratories, Inc. Concentre de solution peg therapeutique
US8507009B2 (en) 2003-11-19 2013-08-13 Salix Pharmaceuticals, Inc. Colonic purgative composition with soluble binding agent
US7687075B2 (en) 2003-11-19 2010-03-30 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
US7718197B2 (en) 2003-11-19 2010-05-18 Salix Pharmaceuticals, Ltd. Colonic purgative composition with soluble binding agent
EP2263680A1 (fr) * 2004-04-23 2010-12-22 Norgine BV Compositions pharmaceutiques comprimés à base de PEG et électrolytes
WO2005102364A1 (fr) * 2004-04-23 2005-11-03 Norgine Europe Bv Compositions pharmaceutiques comprimees comprenant peg et des electrolytes
WO2007085676A1 (fr) * 2006-01-30 2007-08-02 Laboratorios Casen-Fleet, S.L. Procédé de fabrication d'une solution à base de polyéthylèneglycol avec des électrolytes, produit obtenu et son application
ES2278537A1 (es) * 2006-01-30 2007-08-01 Laboratorios Casen-Fleet, S.L. Procedimiento de fabricacion de una solucion a base de polietilenglicol con electrolitos, producto obtenido y uso.
US7495063B2 (en) 2006-02-03 2009-02-24 Dow Global Technologies Inc. Reduced oligomer concentration in high purity polyalkylene glycols
US8597639B2 (en) 2006-08-28 2013-12-03 Miyarisan Pharmaceutical Co., Ltd. Adjunctive agent for lavaging the alimentary canal comprising butyric acid bacterium and/or lactic acid bacterium
WO2009137672A1 (fr) 2008-05-07 2009-11-12 Salix Pharmaceuticals, Ltd. Procédés de traitement de maladie intestinale par l’administration d’un nettoyant d’intestin et d’un antibiotique
US11975020B2 (en) 2009-04-21 2024-05-07 Dark Canyon Laboratories, Llc Colon lavage system
US10555970B2 (en) 2009-04-21 2020-02-11 Dark Canyon Laboratories, Llc Colon lavage system
CN102573499B (zh) * 2009-04-21 2016-03-30 戴尔·R·巴赫威茨 结肠灌洗系统
CN102573499A (zh) * 2009-04-21 2012-07-11 戴尔·R·巴赫威茨 结肠灌洗系统
US8778306B2 (en) 2009-04-21 2014-07-15 Dale R. Bachwich Colon lavage system
GB2478076B (en) * 2009-07-30 2012-06-06 Norgine Bv Polyethylene glycol and electrolyte solutions comprising preservative
GB2472324B (en) * 2009-07-30 2011-10-05 Norgine Bv Polyethylene glycol and electrolyte solutions comprising preservative
GB2472324A (en) * 2009-07-30 2011-02-02 Norgine Bv Polyethylene glycol and electrolyte lavage comprising preservatives for the treatment of constipation or faecal impaction
ES2388095A1 (es) * 2009-07-30 2012-10-08 Norgine Bv Mejoras en y relativas a composiciones farmacéuticas.
US9468686B2 (en) 2009-07-30 2016-10-18 Norgine Bv Solutions comprising polyethylene glycol and electrolytes
GB2478076A (en) * 2009-07-30 2011-08-24 Norgine Bv Polyethylene glycol and electrolyte lavage for the treatment of constipation or faecal impaction
EP2322190A1 (fr) 2009-11-02 2011-05-18 Promefarm S.r.l. Agent de nettoyage intestinal et son utilisation
AU2011356598B2 (en) * 2011-01-28 2017-06-01 William A. Shaver Method, composition and package for bowel cleansing
US10052295B2 (en) 2011-01-28 2018-08-21 William A. Shaver Method, composition and package for bowel cleansing
US9211337B2 (en) 2011-01-28 2015-12-15 Braintree Laboratories, Inc. Method, composition and package for bowel cleansing
WO2012102799A2 (fr) 2011-01-28 2012-08-02 Shaver William A Procédé, composition et module pour le nettoyage de l'intestin
CN103391790A (zh) * 2011-01-28 2013-11-13 威廉·A·沙沃 用于肠道清洁的方法、组合物以及包装
US11241404B2 (en) 2011-01-28 2022-02-08 William A. Shaver Method, composition and package for bowel cleansing
CN105963701A (zh) * 2011-01-28 2016-09-28 布伦特里实验室有限公司 用于肠道清洁的方法、组合物以及包装
US8753618B2 (en) 2011-01-28 2014-06-17 Braintree Laboratories, Inc. Method, composition and package for bowel cleansing
US9566300B2 (en) 2011-01-28 2017-02-14 Braintree Laboratories, Inc. Method, composition and package for bowel cleansing
US10596135B2 (en) 2011-01-28 2020-03-24 William A. Shaver Method, composition and package for bowel cleansing
WO2012102799A3 (fr) * 2011-01-28 2012-10-18 Shaver William A Procédé, composition et module pour le nettoyage de l'intestin
RU2651751C2 (ru) * 2011-01-28 2018-04-23 Уильям А. ШЕЙВЕР Способ, композиция и набор для чистки кишечника
WO2012120027A1 (fr) * 2011-03-08 2012-09-13 Norgine Bv Compositions pour lavement
US10780112B2 (en) 2011-03-11 2020-09-22 Norgine Bv Colonoscopy-preparation
US9592252B2 (en) 2011-03-11 2017-03-14 Norgine Bv Colonoscopy—preparation
US10646512B2 (en) 2011-03-11 2020-05-12 Norgine Bv Colonoscopy - preparation
US10792306B2 (en) 2011-03-11 2020-10-06 Norgine Bv Colonoscopy—preparation
US11529368B2 (en) 2011-03-11 2022-12-20 Norgine Bv Colonoscopy—preparation
US10016504B2 (en) 2012-09-11 2018-07-10 Norgine Bv Compositions
US9707297B2 (en) 2012-09-11 2017-07-18 Norgine Bv Compositions
US8999313B2 (en) 2012-09-11 2015-04-07 Norgine Bv Compositions
US10918723B2 (en) 2012-09-11 2021-02-16 Norgine Bv Colon cleansing compositions and methods of use
US9326969B2 (en) 2012-09-11 2016-05-03 Norgine Bv Compositions
US10471092B2 (en) 2015-01-27 2019-11-12 Apharm S.R.L. Combination of hyaluronic acid and macrogol and pharmaceutical compositions containing it
EA036529B1 (ru) * 2015-01-27 2020-11-19 Афарм С.Р.Л. Комбинация гиалуроновой кислоты и макроголя и фармацевтические композиции, содержащие ее
WO2016120684A1 (fr) * 2015-01-27 2016-08-04 Apharm S.R.L. Combinaison d'acide hyaluronique et de macrogol, et compositions pharmaceutiques la contenant

Also Published As

Publication number Publication date
JP2509594B2 (ja) 1996-06-19
EP0231356A1 (fr) 1987-08-12
AU6196786A (en) 1987-03-05
JPS63500523A (ja) 1988-02-25

Similar Documents

Publication Publication Date Title
WO1987000754A1 (fr) Laxatif a faible teneur en sodium et compositions de lavage
US11241404B2 (en) Method, composition and package for bowel cleansing
Gruy-Kapral et al. Effect of single dose resin-cathartic therapy on serum potassium concentration in patients with end-stage renal disease.
US4975286A (en) Aqueous cathartic solution
Tenenbein et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning
Sondheimer et al. Safety, efficacy, and tolerance of intestinal lavage in pediatric patients undergoing diagnostic colonoscopy
EP2233147A1 (fr) Solution salée pour le nettoyage du colon
SWARTZ et al. Hyperoxaluria and renal insufficiency due to ascorbic acid administration during total parenteral nutrition
Sotos et al. Hypocalcemic coma following two pediatric phosphate enemas
Covey Ferrous sulfate poisoning: a review, case summaries, and therapeutic regimen
Skucas et al. Whole-gut irrigation as a means of cleaning the colon
Jones et al. Cathartic-induced magnesium toxicity during overdose management
Warshawsky et al. Bilateral renal aspergillosis
US7256202B2 (en) Composition and method for treatment of hepatic encephalopathy
Chesney et al. Tetany Following Phosphate: Enemas in Chronic Renal Disease
Kurtzman Renal tubular acidosis: a constellation of syndromes
Helliwell et al. Mortality in sodium chlorate poisoning.
Walker et al. Acute severe intravascular haemolysis: an unrecognised cause of pancreatitis.
Wilder et al. Reabsorptive hyperchloremic acidosis following ureterosigmoidostomy: Report of a severe case showing disturbed carbohydrate metabolism
Kirkman et al. Malignant carcinoid presenting as anuria
Lipman et al. Acute acetylsalicylic acid intoxication
SCHADT et al. Salicylate intoxication in an adult
Lam et al. Fractional excretion of sodium as a guide to volume depletion during recovery from acute renal failure
Berstad et al. Intestinal absorption of calcium from three commercial calcium preparations in man
Bernstein Burns: II: fluid therapy in relation to burn shock and healing

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK JP NO

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1986905052

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1986905052

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1986905052

Country of ref document: EP